Metabolic reprogramming: A novel therapeutic target in diabetic kidney diseaseMengdi Wang, Wenjing Zhao, Yufei Liu et al.|Frontiers in Pharmacology|2022Cited by 41
BaoShenTongLuo formula protects against podocyte injury by regulating AMPK-mediated mitochondrial biogenesis in diabetic kidney disease.Yifan Guo, Wenjing Zhao, Mengdi Wang et al.|Research Square|2023Cited by 1